Age: 31.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19 immunisation, Interchange of vaccine products, No adverse event, Wrong product administered
Clinical narrative: No adverse event; Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022; Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022; Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022; This spontaneous case was reported by a physician and describes the occurrence of COVID-19 IMMUNISATION (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022), INTERCHANGE OF VACCINE PRODUCTS (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022), WRONG PRODUCT ADMINISTERED (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022) and NO ADVERSE EVENT (No adverse event) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Oct-2022, the patient received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 22-Oct-2022, the patient experienced COVID-19 IMMUNISATION (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022), INTERCHANGE OF VACCINE PRODUCTS (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022) and WRONG PRODUCT ADMINISTERED (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, COVID-19 IMMUNISATION (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022), INTERCHANGE OF VACCINE PRODUCTS (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022), WRONG PRODUCT ADMINISTERED (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for COVID-19 IMMUNISATION (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022), INTERCHANGE OF VACCINE PRODUCTS (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022) and WRONG PRODUCT ADMINISTERED (Patient had her first dose of Moderna Monovalent vaccine on 05-Jan-2021, she was then mistakenly given a Pfizer bivalent booster on 22-Oct-2022).    No concomitant medication information was reported. No treatment information was reported.  The reporter asked whether the patient need to receive a second Moderna monovalent vaccine dose to complete her primary series and if the Pfizer bivalent vaccine dose counted as the second dose of the primary series, would the patient be eligible to receive another bivalent booster dose 2 months after that dose.